• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Scilex Holding Company Makes Early Payment for Growth

    GLOBENEWSWIRE

    Scilex Closes $17M Registered Direct Offering

    GLOBENEWSWIRE

    Scilex Holding Announces $17M Registered Direct Offering

    GLOBENEWSWIRE

    Scilex Bio Reports Ph 2 Trial Enrollment for Obesity Results

    GLOBENEWSWIRE

    Scilex Bio Reports KDS2010 Phase 2 Alzheimer’s Trial Enrollment

    GLOBENEWSWIRE

    Scilex Partners IPMC & Bio Open Innovation for Obesity & Alzheimer

    GLOBENEWSWIRE

    NeuroBiogen & Scilex Bio Enter Binding Term Sheet for Licensing

    GLOBENEWSWIRE

    Scilex Holding Company Announces Receipt of Notice from Nasdaq

    GLOBENEWSWIRE

    Scilex to Present Data at 2024 ACR Convergence Conference

    GLOBENEWSWIRE

    Semnur Pharmaceuticals Files S-4 for Business Combo with Denali

    GLOBENEWSWIRE

    Scilex Pharma Announces FDA Meeting for SP-103 Path Forward

    GLOBENEWSWIRE

    Scilex Reiterates Info on Short Selling of Common Stock

    GLOBENEWSWIRE

    Scilex Sets Nov. 7 Record Date for Preferred Stock Dividend

    GLOBENEWSWIRE

    Semnur Provides Timing To File Registration Statement In October

    GLOBENEWSWIRE

    Scilex Explores Value Maximization Options For Scilex Pharmaceuticals

    GLOBENEWSWIRE

    Scilex Holding Announces Closing Of $50 Million Convertible Financing

    GLOBENEWSWIRE

    Scilex Holding Provides Preliminary Q3 2024 Financial Results

    GLOBENEWSWIRE

    Scilex Company Announces Signing of $50 Million Convertible Financing

    GLOBENEWSWIRE

    Hapbee Appoints Mr. Abdulla Al Zain to Board of Directors

    GLOBENEWSWIRE

    Scilex Announces Continuing Support From Endeavor

    GLOBENEWSWIRE

    Scilex Holding Receives NABP Drug Distributor Accreditation

    GLOBENEWSWIRE

    Scilex Announces Presentation At Rheumatology Conference

    GLOBENEWSWIRE

    Scilex To Present On ZTlido At PAINWeek Conference In Las Vegas

    GLOBENEWSWIRE

    Scilex Holding Gets FDA Approval for Precision Dosing GLOPERBA® Label

    GLOBENEWSWIRE

    Scilex To Get New ELYXYB Patent For Acute Pain Treatment

    GLOBENEWSWIRE

    Scilex Holding Provides Preliminary July 2024 Financial Results

    GLOBENEWSWIRE

    Scilex Holding Company Publishes First Sustainability Report

    GLOBENEWSWIRE

    Scilex Appoints Annu Navani To Board Of Directors

    GLOBENEWSWIRE

    Semnur And Denali Capital Enter LOI For Business Combination

    GLOBENEWSWIRE

    Scilex Holding Partners With National Distributor Endeavor Distribution LLC

    GLOBENEWSWIRE

    Scilex Present Poster on ELYXYB® (celecoxib oral solution) at the AHS

    GLOBENEWSWIRE

    Scilex Holding Company Announces That Many National Pharmacy Chains GLOPERBA®

    GLOBENEWSWIRE

    Scilex Holding Company Announces 5-Year Term of $100 Million Financing

    GLOBENEWSWIRE

    Scilex Announces GLOPERBA Stocking Underway Across US Wholesalers

    GLOBENEWSWIRE

    Scilex: FDA Approves sNDA For Gloperba® US Launch Week Of June 10th 2024

    GLOBENEWSWIRE

    Scilex Alleges Illegal Stock Manipulation Writes To Regulators

    GLOBENEWSWIRE

    Scilex Letter To Us House: On Illegal Stock Market Manipulation

    GLOBENEWSWIRE

    Scilex Added To Msci Index: Global Microcap Companies Inclusion

    GLOBENEWSWIRE

    Scilex Provides Info On Manipulative Short Selling Of Its Common Stock

    GLOBENEWSWIRE

    Scilex Holding Company Announces $15 Million Registered Direct Offering

    GLOBENEWSWIRE

    Scilex Provides Q1 2024 ZTlido Sales, Plans 2024 Ramp for Opioid Sparing Product

    GLOBENEWSWIRE

    Scilex Launches Co-Pay Programs, Expands Medicaid Access

    GLOBENEWSWIRE

    Scilex Announces that the U.S. Bankruptcy Court has Extended the Lockup Period

    GLOBENEWSWIRE

    Scilex Announces New Out-of-Pocket Costs for Commercially Insured Patients

    GLOBENEWSWIRE

    Scilex Company Announces a Settlement Agreement with Takeda Pharma Paragraph IV

    GLOBENEWSWIRE

    Scilex Holding Company Announces Repayment in Full of the Remaining Balance

    GLOBENEWSWIRE

    Scilex Provides Responses to Composition Questions Related to its ELYXYB Patent

    GLOBENEWSWIRE

    Scilex Entered into a Agreement with Virpax Pharmaceuticals

    GLOBENEWSWIRE

    Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product

    GLOBENEWSWIRE

    Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba

    GLOBENEWSWIRE

    Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering

    GLOBENEWSWIRE

    Scilex Announces that Official Committee of Unsecured Creditors of Sorrento

    GLOBENEWSWIRE

    Scilex Holding Company Announces $10 Million Bought Deal Offering

    GLOBENEWSWIRE

    Scilex Announces Initiative with a National Pharmacy Chain to Stock GLOPERBA

    GLOBENEWSWIRE

    Virpax Announces Proposed Settlement of Litigation with Sorrento Therapeutics

    BUSINESSWIRE

    Scilex Pharmaceuticals Enters into a Term Sheet with Virpax Pharmaceuticals

    GLOBENEWSWIRE

    Scilex Holding Company Announces Publication of Results from Study Using ZTlido

    GLOBENEWSWIRE

    Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results

    GLOBENEWSWIRE

    Scilex Holding Company Announces Filing of a NDS for the Approval of ELYXYB

    GLOBENEWSWIRE

    Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.